Gong W.-P.,Shengzhou Peoples Hospital |
Guo Q.-H.,Fudan University |
Zhao Q.-H.,Fudan University |
Hong Z.,Fudan University
National Medical Journal of China | Year: 2012
Objective: To provide rationales for the prevention and treatment of elderly patients with cognitive disorders through comparing the comorbidities according to different etiologies and severities. Methods: Six groups of different cognitive status were selected. There were 438 normal cognitive subjects (NC) from Jing'an community of Shanghai. Five other groups were from the Memory Clinic at our hospital from June 2006 to June 2010. There were subjective memory complaints (n = 443, SMC), mild cognitive impairment (n =540, MCI), vascular cognitive impairment-non dementia (n = 119, VCI-ND), Alzheimer's disease (n =337, AD) and vascular dementia (n = 54, VaD). All participants finished a battery of neuropsychological tests and completed the survey of such comorbidities as stroke, conscious disturbance, hypertension, diabetes, head injuries and excessive drinking. Results: The comorbidity rates of diabetes were 11.4%, 9.9%, 16.1%, 14.2%, 12.4% and 18.5% in 6 groups (NC, SMC, MCI, VCI-ND, AD, VaD) respectively. There were no differences for overall or pairwise chi square tests. The rates of stroke, hypertension and excessive drinking in patients of VCI-ND and VaD were higher than those of SMC, MCI and AD. The comorbidity rates in the VCI-ND and VaD group were 54.6% vs 62.9% for stroke; 61.3% vs 79.6% for hypertension; 22.6% vs 37.0% for excessive drinking. Whereas in the SMC, MCI and AD groups, the rates were 9.4%, 10.9% and 3.0% for stroke; 44.9%, 47.2% and 42.1% for hypertension; 18.0%, 18.3% and 15.1% for excessive drinking. No distinct differences existed for the comorbidity rates among SMC, MCI and AD groups or among different degrees of AD. Conclusion: Etiologies rather than severities determine the different rates of comorbidities in the elders with cognitive impairment. Copyright © 2012 by the Chinese Medical Association.
Wang P.,Shengzhou Peoples Hospital |
Ruan H.-F.,Zhejiang University |
Lou J.-Y.,Zhejiang University
Journal of Practical Oncology | Year: 2013
To investigate the inhibitive effect of adenovirus-mediated shRNA targeting Akt2 on the invasive ability of gastric cancer SCG-7901 cells in vitro. The Akt2 shRNA adenovirus vector was constructed and transfected to SCG-7901 cells, the pEGFP-empty gene adenovirus vector was used as the control. Real time-PCR and Western blot were used to detect the expression of Akt2, and transwell assay was used to detect the invasive ability of SCG-7901 cells. Compared with the control group, the expression of Akt2 mRNA and protein in Akt2 shRNA group was 26% and 31% (P < 0.05), respectively. And the invasive ability of SGC-7901 cells was decreased more than 50%. Akt2 shRNA can decrease Akt2 expression and inhibit the invasive ability of SGC-7901 cells in vitro.
Dong X.-Q.,The First Hangzhou Municipal Peoples Hospital |
Yang S.-B.,Shengzhou Peoples Hospital |
Zhu F.-L.,Shengzhou Peoples Hospital |
Lv Q.-W.,Shengzhou Peoples Hospital |
And 2 more authors.
Critical Care | Year: 2010
Introduction: Recently, we reported that high levels of resistin are present in the peripheral blood of patients with intracerebral hemorrhage and are associated with a poor outcome. However, not much is known regarding the change in plasma resistin and its relation with mortality after traumatic brain injury (TBI). Thus, we sought to investigate change in plasma resistin level after TBI and to evaluate its relation with disease outcome.Methods: Fifty healthy controls and 94 patients with acute severe TBI were included. Plasma samples were obtained on admission and at days 1, 2, 3, 5 and 7 after TBI. Its concentration was measured by enzyme-linked immunosorbent assay.Results: Twenty-six patients (27.7%) died from TBI within 1 month. After TBI, plasma resistin level in patients increased during the 6-hour period immediately after TBI, peaked within 24 hours, plateaued at day 2, decreased gradually thereafter and was substantially higher than that in healthy controls during the 7-day period. A forward stepwise logistic regression selected plasma resistin level (odds ratio, 1.107; 95% confidence interval, 1.014-1.208; P = 0.023) as an independent predictor for 1-month mortality of patients. A multivariate linear regression showed that plasma resistin level was negatively associated with Glasgow Coma Scale score (t = -6.567, P < 0.001). A receiver operating characteristic curve identified plasma resistin cutoff level (30.8 ng/mL) that predicted 1-month mortality with the optimal sensitivity (84.6%) and specificity (75.0%) values (area under curve, 0.854; 95% confidence interval, 0.766-0.918; P < 0.001).Conclusions: Increased plasma resistin level is found and associated with Glasgow Coma Scale score and mortality after TBI. © 2010 Dong et al.; licensee BioMed Central Ltd.
Zhou H.,Zhejiang University |
Wang G.,Shengzhou Peoples Hospital |
Lu Y.,Zhejiang University |
Pan Z.,Zhejiang University
Biomaterials Science | Year: 2016
In this study, cisplatin (cis-diaminedichloroplatinum, CDDP) nanocarriers with phosphorylcholine surface tailoring were developed to enhance the anti-tumor potential of CDDP for the treatment of osteosarcoma. Poly(2-methacryloyloxyethyl phosphorylcholine)-b-poly(methacrylic acid) (PMPC-b-PMAA) was synthesized for the preparation of CDDP/PMPC-b-PMAA micelles. The synthesis, self-assembly, and in vitro drug release were well characterized. In vitro cytotoxicity showed that CDDP/PMPC-b-PMAA micelles can strongly inhibit the proliferation of Saos-2 cells. In vivo experiments indicated that CDDP/PMPC-b-PMAA micelles showed prolonged circulation time, reduced renal accumulation, and enhanced tumor accumulation compared to free CDDP. Overall, the CDDP/PMPC-b-PMAA micelles exhibited optimal anti-tumor activity with minimal side effects in the treatment of osteosarcoma. © 2016 The Royal Society of Chemistry.
Xu J.-F.,Zhejiang University |
Liu W.-G.,Zhejiang University |
Dong X.-Q.,Nanjing Medical University |
Yang S.-B.,Shengzhou Peoples Hospital |
Fan J.,Zhejiang University
Journal of Trauma and Acute Care Surgery | Year: 2012
BACKGROUND: Plasma gelsolin depletion has been associated with poor outcome of critically ill patients. However, there is a paucity of data available on circulating plasma gelsolin concentration in traumatic brain injury (TBI). Thus, we sought to investigate change in plasma gelsolin level after TBI and to evaluate its relation with disease outcome. METHODS: Fifty healthy controls and 94 patients with acute severe TBI were included. Plasma samples were obtained on admission and at days 1, 2, 3, 5, and 7. Its concentration was measured by enzyme-linked immunosorbent assay. RESULTS: Twenty-six patients (27.7%) died from TBI in a month. After TBI, plasma gelsolin level in patients decreased during the 6-hour period immediately, was at the nadir in 24 hours, increased gradually thereafter, and was substantially lower than that in healthy controls during the 7-day period. A multivariate analysis showed plasma gelsolin level was an independent predictor for 1-month mortality (odds ratio, 0.941; 95% confidence interval, 0.895-0.989; p = 0.017) and positively associated with Glasgow Coma Scale (GCS) score (t = 6.538, p < 0.001). A receiver operating characteristic curve identified that a baseline plasma gelsolin level <52.7 mg/L predicted 1-month mortality with 88.5% sensitivity and 79.4% specificity (area under the curve, 0.869; 95% confidence interval, 0.783-0.930). The predictive value of the gelsolin concentration was thus similar to that of GCS scores (p = 0.185). However, gelsolin did not statistically significantly improve the area under the curve of GCS scores (p = 0.517). CONCLUSIONS: Decreased plasma gelsolin level is associated with GCS scores and an independent prognostic marker of mortality after TBI. Reversing plasma gelsolin deficiency may be an effective treatment for TBI. Copyright © 2012 by Lippincott Williams & Wilkins.